Associations between elevated kidney and liver biomarker ratios, metabolic syndrome and all-cause and coronary heart disease (CHD) mortality: analysis of the U.S. National Health and Nutrition Examination Survey (NHANES)

Akinkunle Oye-Somefun*, Jennifer L. Kuk and Chris I. Ardern

Abstract

Background: We examined the relationship between ratios of select biomarkers of kidney and liver function on all-cause and coronary heart disease (CHD) mortality, both in isolation, and in combination with metabolic syndrome (MetS), among adults (20+ years, n = 10,604).

Methods: Data was derived from the U.S. National Health and Nutrition Examination Survey (1999–2016) including public-use linked mortality follow-up files through December 31, 2015.

Results: Select biomarker ratios of kidney (UACR or albuminuria and BUN-CR) and liver (AST-ALT and GGT-ALP) function in isolation and in combination with MetS were associated with all-cause and CHD mortality. Compared to individuals with neither elevated biomarker ratios nor MetS (HR = 1.00, referent), increased risk of all-cause mortality was observed in the following groups: MetS with elevated UACR (HR = 2.57, 1.99–3.33), MetS with elevated AST-ALT (HR = 2.22, 1.61–3.07), elevated UACR without MetS (HR = 2.12, 1.65–2.72), and elevated AST-ALT without MetS (HR = 1.71, 1.35–2.18); no other biomarker ratios were associated with all-cause mortality. For cause-specific deaths, elevated risk of CHD mortality was associated with MetS with elevated UACR (HR = 1.67, 1.05–2.67), MetS with elevated AST-ALT (HR = 2.80, 1.62–4.86), and elevated BUN-CR without MetS (HR = 2.12, 1.12–4.04); no other biomarker ratios were associated with CHD mortality.

Conclusion: Future longitudinal studies are necessary to examine the utility of these biomarker ratios in risk stratification for chronic disease management.

Keywords: Biomarkers, Kidney function, Metabolic syndrome, Mortality, NHANES, Obesity

Introduction

Current estimates are that one-third of all adults in the United States (U.S.) have the metabolic syndrome (MetS)—a cluster of cardiometabolic conditions that are leading contributors to an elevated risk for cardiovascular disease (CVD) and type II diabetes [1–3]. While the major complications of MetS are now well defined, a number of related consequences have been identified, including an increased risk of fatty liver disease [4–6], renal failure [7–9], and low grade chronic inflammation [10–15], that collectively increase risk of premature death [16–20].
Over the past three decades, the contribution of a host of biomarkers to morbidity and mortality has received increasing attention [5, 6, 8–10, 16–25]. Included in these are validated molecular biomarkers, such as liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT), that serve as reliable indicators of past exposures and future adverse cardiometabolic abnormalities [22–25]. Liver enzymes are routinely evaluated—in isolation, or less frequently as ratios—when investigating suspected biliary conditions, or liver conditions such as non-alcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD) [5, 6, 22–25]. Similarly, surrogates of kidney disease such as urinary albumin, urinary creatinine, blood urea nitrogen, and serum creatinine, help to underscore the interrelated nature of renal pathology [16–21].

Until recently, little was known about the co-occurrence of these biomarkers in cardiometabolic disease, but in recent years, the application of validated molecular biomarkers in the study of cardiovascular and metabolic pathways has been increasing [17, 19–25]. The ratios of these biomarkers have therefore been proposed as a way to advance the risk assessment process [5, 15]. Of note, albuminuria—which can be characterized as elevated urinary albumin to creatinine (UACR) ratio—is recognized by the World Health Organization as a stand-alone component within its criteria for MetS [1, 4]. Elevated kidney biomarkers suggest vascular injury of the kidneys and systemic endothelial dysfunction [8, 9, 16–21], whereas elevated liver enzymes may reflect liver dysfunction related to alcohol abuse [22], insulin resistance [23], or impaired perfusion [10, 11, 24], which has also been linked to venous congestion and renal dysfunction [9, 20]. Given the interrelationship, endothelial dysfunction [9], impaired perfusion or cardiac output [10], and systemic inflammation [11] are a few of the common underlying mechanisms of abnormal kidney or liver biomarkers [10, 16, 17].

To date, the use of various kidney or liver biomarker ratios to predict mortality, are nevertheless lacking in large-scale or population-based studies involving cardiovascular disease endpoints. Moreover, the combined effect of biomarkers and MetS on mortality has not been fully evaluated, however, even as emerging evidence now supports their use in diagnostic algorithms to help in the identification of high-risk groups [5, 20, 24, 25, 29]. Building on previous studies on kidney [17–21, 25] and liver [15, 16, 22–25] biomarkers to explore the utility of co-occurring biomarkers ratios may provide new insight into their independent and joint effects on mortality. Previous analysis of the U.S. National Health and Nutrition Examination Survey (NHANES) have also relied on the Beckman CX3 using a Jaffé reaction method of assessment for serum and urine creatinine [26, 27], which has recently been updated with a correction factor, and warrants re-analysis [27].

The purpose of this study is to examine the independent and joint associations of kidney and liver biomarker ratios with MetS on all-cause and CHD mortality, using public-use linked mortality files for the U.S. NHANES. We hypothesize that elevated ratios of biomarkers both in isolation, and in combination with MetS will be associated with all-cause and cause-specific deaths, compared to the referent groups—adults with (1) no MetS nor elevated ratios, and; (2) prevalent MetS only.

Methods

Database

Data for this study was derived from multiple cycles of the cross-sectional Continuous NHANES. The Continuous NHANES uses a complex, multistage, probability cluster design in order to yield a nationally representative survey of the health and nutritional status of the non-institutionalized civilian population in the U.S., full details on which are described in the NHANES survey methods and analytic guidelines [30]. Ethics approval was obtained from the National Center for Health Statistics Research Ethics Review Board (ERB) for NHANES 1999–2004 (Protocol #98-12), NHANES 2005–2010 (Protocol #2005-06), NHANES 2011–2016 (Protocol #2011-17) on which data for this analysis was used. Informed, written consent was obtained from all participants. This study is an analysis of NHANES publicly available anonymized data, and thus, does not require further ethical review from the York University institutional review board.

Study sample

The original sample is an amalgamation of nine consecutive cycles collected in 2-year increments from 1999 through 2016 of the continuous NHANES. The initial unweighted sample size was 92,062 (Fig. 1). A final analytical sample of 13,731 was obtained for the cross-sectional analysis after listwise exclusion of individuals under 20 years of age (n = 42,550), women who were pregnant (n = 1486), those reporting (yes/no) use of mobility aids (n = 4581), cases with less than eight hours of overnight fasting (n = 21,745), cases without fasting sampling weights (n = 3970), those reporting (yes/no) any liver (n = 636) or kidney (n = 431) conditions, and missing data for covariates.

Data collection

Information on demographic, lifestyle, physical measurements, and standard biochemistry profiles were collected. Standardized physical examinations, and laboratory tests,
were performed in controlled environments [27]. Trained field health technicians conducted interviews at each mobile exam center (MEC), performed physical examinations (e.g., height, weight, waist circumference and blood pressure), as well as biospecimens (blood and urine) collection, which includes screening for pregnancy, storing, and shipping of biospecimens [27].
Standard biochemistry profile
The NHANES Laboratory Method Files offer detailed description of the biological specimen collection, storage, and laboratory methods used [27]. Clinical biospecimens were often analyzed using either a Beckman Synchron LX20 prior to the 2007–2008 cycle, or a Beckman UniCel DxC 800 Synchron after the 2007–2008 cycle because of an instrumentation change in 2007 [27]. Coefficient of variation (CV) for all laboratory biomarkers were assessed using univariate analysis, and deemed to be within acceptable range (<10%) [27, 31, 32].

Serum ALT and ALP activity were determined using a kinetic rate method, while an enzymatic rate method was used to determine AST and GGT activity [27]. An enzymatic conductivity rate method was also used to determine the concentration of blood urea nitrogen (BUN) [27]. Serum creatinine (CR) concentration was determined using a Jaffé rate method (kinetic alkaline picrate); however, CR from the periods 1999–2000 and 2005–2006 were determined to have bias due to a lack of standardized methods, or calibration [26]. In order to adjust CR for those cycles, a correction factor was recommended [27].

Glucose concentration was determined using a hexokinase-mediated reaction method, while a timed-endpoint method was used to determine the concentration of serum triglycerides [27]. Despite changes in the lab site, method, and instrumentation to measure triglycerides across cycles, no adjustments were deemed necessary as a result of these changes.

High density lipoprotein (HDL) cholesterol was analyzed in 1999–2002 primarily by heparin manganese precipitation or by direct HDL immunoassay depending on the participant age and amount of specimen [27]. Beginning in 2003, all specimens were analyzed using the direct HDL cholesterol immunoassay method, and in 2007–2008, a new laboratory performed the direct HDL cholesterol method on a different instrument [27]. HDL cholesterol values for 1999–2000, 2001–2002 and 2005–2006 were therefore adjusted to account for changes in instrumentation and methods using the CDC correction factor set out by Solomon Park Research Laboratories (Kirkland, WA) quality controls correction factor [27]. With the exception of HDL values for 1999–2002, which could not be evaluated, all laboratories were within the 5% maximum allowable bias for HDL [27].

Urinary albumin (UA) was measured using a solid-phase fluorescent immunoassay, which is a non-competitive, double-antibody method [27]. A Beckman Synchron CX3 Clinical Analyzer Jaffé rate reaction method was used to measure urinary creatinine (UCR) by enzymatic method prior to 2007 [27]. Due to an instrument change in 2007–2008, UCR was measured using Roche/Hitachi Modular P Chemistry Analyzer [27]. In accordance with recommendations, a piecewise regression approach was used to adjust UCR prior to 2007 to be comparable with UCR from 2007 onwards [27].

Public-use linked mortality files (LMF)
The outcomes for this study were all-cause and CHD mortality. The public-use versions of the LMF include a limited set of mortality variables for adult participants only after files were processed to reduce the participant disclosure risk. The public-use LMF provides mortality follow-up data from the date of survey participation through the end of the mortality period—December 31, 2015 (sample size for this analysis, n = 10,604). Data collected from the National Center for Health Statistics (NCHS) has linked several population surveys with death certificate records from the National Death Index (NDI) [35]. All-cause mortality included all known as well as unknown causes, while CHD mortality was defined as diseases of the heart using international classification of diseases coding (ICD-9 and ICD-10), including: diseases of heart (I00–I09, I11, I13, I20–I51), acute rheumatic fever and chronic rheumatic heart diseases (I00–I09), hypertensive heart disease (I11), hypertensive heart and renal disease (I13), ischemic heart diseases (I20–I25), acute myocardial infarction (I21–I22), other acute ischemic heart diseases (I24), other forms of chronic ischemic heart disease (I20, I25), and atherosclerotic cardiovascular disease (I25.0), all other forms of chronic ischemic heart disease (I20, I25.1–I25.9), and other heart diseases (I26–I151) [35].

Markers of cardiometabolic risk
Screening for MetS included the presence of three or more of the following five risk factors: high triglycerides (≥150 mg/dl); reduced high-density lipoprotein cholesterol (<40 mg/dl [males] and ≤50 mg/dl [females]); high fasting glucose (≥100 mg/dl or diabetes medications); high blood pressure (systolic ≥130 mmHg or diastolic ≥85 mmHg, or hypertension medications), and; high waist circumference (≥102 cm [males] and ≥88 cm [females]) [1, 4]. Comorbid conditions (CVD, diabetes, and hypertension) were determined using self-reports of medical conditions informed by a doctor or health professional [27].

For serum biomarkers, the Johns Hopkins Hospital’s Harriet Lane Handbook was consulted for the general population or sex-specific reference ranges [33]. For urinary biomarkers, the CDC reference ranges were consulted [27]. Biomarkers were selected and computed as ratios on the basis of previous research that established a link with insulin resistance or MetS [1, 4, 6, 15, 23]. Because biomarkers may vary by clinical laboratory
settings, instrumentation, or method, a 90th percentile cut-off level was deemed as an acceptable "high-normal" to have consistency between biomarkers and sufficient group sizes for the pooled data [34]; survey cycles were pooled for the purpose of the current analysis. Elevated biomarker ratios were therefore categorized using the 90th percentile cut-offs for the pooled data as follows: BUN-CR (≥ 21.21 mg/dL), GGT-ALP (≥ 0.71 U/L), and AST-ALT (≥ 1.47 U/L). A urinary albumin to creatinine ratio (UACR) was determined by NHANES laboratory protocol [27]. Established threshold for low UACR (normoalbuminuria (< 30 mg/g)) and elevated UACR (albuminuria (≥ 30 mg/g)), were used [1, 4].

Participants were subsequently cross-classified into four discrete groups: (1) non-MetS with non-elevated biomarker ratio; (2) non-MetS with elevated biomarker ratio; (3) MetS with non-elevated biomarker ratio, and; (4) MetS with elevated biomarker ratio.

Covariates
All analyses were adjusted for age, sex, ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, Other/Multi-Ethnic), education, income status (a ratio of household income to the related poverty cut-off level), alcohol status (“had at least 12 drinks in a year”), lifetime smoking status (“had at least 100 cigarettes in life”), self-reported general health, health insurance coverage, healthcare utilization (frequency of hospital visits), physical activity (PA), and survey collection year [27]. Weekly minutes of moderate or vigorous-intensity PA was ascertained and used to categorize participants as “low” (<150 min/week), or “high” (≥ 150 min/week), consistent with current PA guidelines [27].

Statistical analysis
Our first objective was to determine the prevalence and cross-sectional association between biomarkers ratios and MetS with prevalent CVD. In an initial step, sociodemographic, health, and behavioral characteristics of the sample were compared between those with versus without MetS using t-tests and chi-squared analysis, as appropriate. Biomarker ratios (mean ± SEM), and the prevalence of elevated biomarker ratios, were compared between groups with and without MetS using t-tests and chi-square, respectively. Unadjusted and fully adjusted (for covariates: age, sex, ethnicity, education, income, alcohol, smoking status, self-reported general health, health insurance coverage, frequency of hospital visits, physical activity, and survey collection year) logistic regression models were used to assess the independent and joint associations of the MetS/biomarker groups with CVD in a sensitivity analysis (n=13,731). Using these groups, the proportional hazards assumption was subsequently assessed and upheld. For the mortality analysis (n=10,604), a final series of Cox proportional hazards regression models (semi-parametric) were developed to examine the unadjusted and fully adjusted (for covariates) relationship for each discrete category of biomarkers with the referent (i.e., no MetS nor elevated ratios, and; prevalent MetS) and all-cause or CHD mortality (HR=1.00, referent). A hazard ratio greater than the null value (HR=1.00) suggests a higher risk for the event (or lower risk when less than the null). Data analysis was performed with SAS software version 9.4 (Cary, NC, U.S.A.), weighted with the master survey weights to ensure national representativeness of the data. Statistical significance was set at alpha = 0.05.

Results
Table 1 shows the sociodemographic and clinical characteristics among participants with and without MetS (p<0.01). Of note, MetS was more prevalent in older age, and had a higher proportion of males, Mexican Americans, and non-Hispanic Whites, compared to the non-MetS group. The MetS group had a higher proportion of individuals without college education and lower incomes, compared to the non-MetS group. The MetS group also had a higher proportion of smokers, more frequent hospital visits, insurance coverage, lower self-rated health, and more inactivity, compared to the non-MetS group.

Overall, the prevalence of elevated biomarker ratios for MetS and non-MetS groups showed that the MetS group had a higher proportion with elevated kidney biomarkers (UACR or albuminuria, and BUN-CR), and elevated liver biomarkers GGT-ALP. As well, the MetS group tended to have higher mean ratios for UACR, BUN-CR, GGT-ALP, compared to the non-MetS group.

All-cause mortality
Results of the unadjusted and fully adjusted (for covariates) Cox proportional hazards models of the association between all-cause mortality and co-occurrence of MetS with kidney, or liver, biomarker ratios are presented in tables (see Additional file 1). In the fully adjusted model of the analytic sample (Fig. 2), elevated biomarker ratio with prevalent MetS (elevated UACR: HR, 95% CI = 2.57, 1.99–3.33, and elevated AST-ALT: HR = 2.22, 1.61–3.07) was positively associated with all-cause mortality, compared to the referent group—that is, the group with neither elevated biomarker ratio nor MetS. Positive associations with all-cause mortality were also observed for these elevated biomarker ratios without MetS (elevated UACR: HR = 2.12, 1.65–2.72, and elevated AST-ALT: HR = 1.71, 1.35–2.18), compared to referent. By contrast, there were no associations for
Table 1 Characteristics of Adults (20+ years), NHANES 1999–2016

| Analytic sample | Total | MetS |
|-----------------|-------|------|
| (n = 13,731)    |       |      |
| MetS (%)        | 69.11 | 30.89|
| Age (y): Mean (SEM) | 45.76 | 51.42|
| Sex: Males (%)  | 49.76 | 50.24|
| Education       |       |      |
| Less than High School (%) | 15.80 | 14.26|
| College Education (%) | 60.99 | 64.54|
| Income ratio: mean (SEM) | 3.09 | 3.13|
| < 1.3 (%)       | 18.94 | 20.39|
| 1.3–3.5 (%)     | 36.33 | 37.82|
| > 3.5 (%)       | 44.73 | 41.80|
| Alcohol: Yes (%)| 76.85 | 72.15|
| Smoking: Yes (%)| 46.09 | 49.73|
| Hospital visits |       |      |
| None (%)        | 17.52 | 15.14|
| 1 visit (%)     | 20.12 | 17.27|
| 2–9 visits (%)  | 22.53 | 26.64|
| ≥ 10 visits (%) | 9.87  | 11.67|
| Insurance: Yes (%) | 81.95 | 83.80|
| Health status: poor/fair (%) | 13.08 | 19.32|
| Physical activity minutes per week: mean (SEM) | 609.51 | 528.38|

Table 1 (continued)

| Analytic sample | Total | MetS |
|-----------------|-------|------|
| (n = 13,731)    |       |      |
| Cardiovascular disease (%) | 5.14  | 3.76 |
| Coronary heart disease (%) | 2.55  | 1.97 |
| Heart attack (%) | 2.39  | 1.69 |
| Stroke (%)      | 1.86  | 1.33 |
| UACR ratio: mean (SEM) | 19.35 | 13.49|
| Elevated (%)    | 7.76  | 5.61 |
| BUN-CR ratio: mean (SEM) | 15.07 | 14.87|
| Elevated (%)    | 11.39 | 10.48|
| GGT-ALP ratio: mean (SEM) | 0.41  | 0.28|
| Elevated (%)    | 10.00 | 7.88 |
| AST-ALT ratio: mean (SEM) | 1.08  | 1.12|
| Elevated (%)    | 10.10 | 12.26|

Prevalence of elevated biomarker ratios, including socio-demographic, health, and behavioral characteristics compared between adults with versus without MetS using t-tests and chi-squared analysis, as appropriate. All P < .01; chi-square for frequencies, and independent sample t-test for continuous measures. Values in parentheses represent SEM for continuous measures or SE for proportions.

the following groups: those with an elevated biomarker ratio without MetS (elevated BUN-CR: HR = 1.05, 0.79–1.39; elevated GGT-ALP: HR = 1.24, 0.92–1.67), MetS without elevated biomarker ratio (normoalbuminuria: HR = 1.05, 0.89–1.24; BUN-CR: HR = 1.10, 0.93–1.31; GGT-ALP: HR = 1.12, 0.96–1.32; AST-ALT: HR = 1.17, 1.00–1.38), and MetS with elevated biomarker ratio (elevated BUN-CR: HR = 1.26, 0.96–1.64; elevated GGT-ALP: HR = 1.26, 0.95–1.67), compared to referent. In a subsample without self-reported comorbidities (CVD, diabetes, or hypertension), the relationships in the fully adjusted (for covariates) model were maintained (Table 2); in addition, there was a statistically significant association between elevated GGT-ALP with MetS (HR = 1.39, 1.02–1.90) and all-cause mortality, compared to referent.

In fully adjusted models using prevalent MetS as the referent group (Table 3) there was a positive association between elevated biomarker ratio without MetS (elevated UACR: HR = 2.03, 1.56–2.63, and elevated AST-ALT: HR = 1.46, 1.13–1.89), and elevated biomarker
ratio with MetS (elevated UACR: HR = 2.46, 1.96–3.11, and elevated AST-ALT: HR = 1.89, 1.40–2.57), and all-cause mortality. No associations were observed for the following groups: neither elevated biomarker ratio nor MetS, and; elevated biomarker ratio with/without MetS (BUN-CR and GGT-ALP).
Detailed analysis of the relationship between CHD mortality and co-occurrence of MetS with kidney, or liver, biomarker ratios are presented in the additional tables. In fully adjusted models (Fig. 2), CHD mortality was positively associated with the following groups: elevated biomarker ratio with MetS (elevated UACR: HR = 1.67, 1.05–2.67, and elevated AST-ALT: HR = 2.80, 1.62–4.86), and elevated BUN-CR without MetS (HR = 2.12, 1.12–4.04), compared to the referent group with neither elevated biomarker ratio nor MetS. No associations were observed for groups with elevated biomarker ratio without MetS (elevated UACR: HR = 1.22, 0.66–2.16; GGT-ALP: HR = 1.4, 0.8–2.7; AST-ALT: HR = 1.0, 0.6–1.8; and BUN-CR: HR = 1.0, 0.6–1.8), MetS without elevated biomarker ratio (normoalbuminuria: HR = 0.83, 0.54–1.26; BUN-CR: HR = 1.22, 0.66–2.16; GGT-ALP: HR = 1.40, 0.76–2.58), and MetS with elevated biomarker ratio (BUN-CR: HR = 0.81, 0.40–1.64; GGT-ALP: HR = 0.81, 0.45–1.48), compared to referent. In a subsample without self-reported comorbidities (CVD, diabetes, or hypertension), only MetS with elevated AST-ALT (HR = 3.11, 1.49–6.49) was positively associated with CHD mortality (Table 4).

**Table 2** Association between all-cause mortality and kidney or liver biomarker ratio with or without MetS (referent)

| Biomarkers | Groups | Unadjusteda | Adjustedb | Adjustedc |
|------------|--------|-------------|------------|-----------|
|            | MetS status | High biomarker ratio | Hazard ratiosa 95% confidence interval | Hazard ratiosb 95% confidence interval | Hazard ratiosc 95% confidence interval |
| UACR       | No      | No          | 1.00 (REF) – | 1.00 (REF) – | 1.00 (REF) – |
|            | No      | Yes         | 4.12 3.16 to 5.37 | 2.12 1.65 to 2.72 | 2.07 1.53 to 2.79 |
|            | Yes     | No          | 1.93 1.64 to 2.26 | 1.05 0.89 to 1.24 | 1.04 0.86 to 1.24 |
|            | Yes     | Yes         | 6.11 4.78 to 7.80 | 2.57 1.99 to 3.33 | 2.40 1.76 to 3.26 |
| BUN-CR     | No      | No          | 1.00 (REF) – | 1.00 (REF) – | 1.00 (REF) – |
|            | No      | Yes         | 1.63 1.23 to 2.16 | 1.05 0.79 to 1.39 | 0.99 0.71 to 1.38 |
|            | Yes     | No          | 2.02 1.71 to 2.39 | 1.10 0.93 to 1.31 | 1.09 0.90 to 1.31 |
|            | Yes     | Yes         | 3.38 2.66 to 4.28 | 1.26 0.96 to 1.64 | 1.12 0.82 to 1.54 |
| GGT-ALP    | No      | No          | 1.00 (REF) – | 1.00 (REF) – | 1.00 (REF) – |
|            | No      | Yes         | 1.45 1.06 to 1.99 | 1.24 0.92 to 1.67 | 1.21 0.88 to 1.65 |
|            | Yes     | No          | 2.17 1.87 to 2.53 | 1.12 0.96 to 1.32 | 1.07 0.90 to 1.28 |
|            | Yes     | Yes         | 2.07 1.54 to 2.77 | 1.26 0.95 to 1.67 | 1.39 1.02 to 1.90 |
| AST-ALT    | No      | No          | 1.00 (REF) – | 1.00 (REF) – | 1.00 (REF) – |
|            | No      | Yes         | 2.25 1.78 to 2.85 | 1.71 1.35 to 2.18 | 1.69 1.30 to 2.21 |
|            | Yes     | No          | 2.19 1.88 to 2.55 | 1.17 1.00 to 1.38 | 1.15 0.97 to 1.37 |
|            | Yes     | Yes         | 6.71 4.83 to 9.34 | 2.22 1.61 to 3.07 | 2.09 1.46 to 3.00 |

Data derived from NHANES 1999–2015; referent group has neither elevated biomarker ratio nor MetS. Covariates include age, sex, ethnicity, education, income ratio, alcohol use, smoking, hospital visits, insurance coverage, self-rated health, and physical activity

a Unadjusted model of the analytic subsample (n = 10,604); n = 1215 deaths
b Fully adjusted model of the analytic subsample (n = 10,604); n = 1215 deaths
c Fully adjusted model of a subsample without self-reported CVD, diabetes, or hypertension (n = 9909); n = 970 deaths

**CHD mortality**

Detailed analysis of the relationship between CHD mortality and co-occurrence of MetS with kidney, or liver, biomarker ratios are presented in the additional tables. In fully adjusted models (Fig. 2), CHD mortality was positively associated with the following groups: elevated biomarker ratio with MetS (elevated UACR: HR = 1.67, 1.05–2.67, and elevated AST-ALT: HR = 2.80, 1.62–4.86), and elevated BUN-CR without MetS (HR = 2.12, 1.12–4.04), compared to the referent group with neither elevated biomarker ratio nor MetS. No associations were observed for groups with elevated biomarker ratio without MetS (elevated UACR: HR = 1.22, 0.66–2.16; GGT-ALP: HR = 1.40, 0.76–2.58), MetS without elevated biomarker ratio (normoalbuminuria: HR = 0.83, 0.54–1.26; BUN-CR: HR = 1.22, 0.66–2.16; GGT-ALP: HR = 1.40, 0.76–2.58), and MetS with elevated biomarker ratio (BUN-CR: HR = 0.81, 0.40–1.64; GGT-ALP: HR = 0.81, 0.45–1.48), compared to referent. In a subsample without self-reported comorbidities (CVD, diabetes, or hypertension), only MetS with elevated AST-ALT (HR = 3.11, 1.49–6.49) was positively associated with CHD mortality (Table 4).

In a final set of models (unadjusted and adjusted for covariates), we explored the contribution of MetS to CHD mortality using prevalent MetS as the referent group (Table 5) and found a positive association between CHD mortality and elevated biomarker ratio with MetS (elevated UACR: HR = 2.03, 1.28–3.22, and elevated AST-ALT: HR = 3.20, 1.86–5.51). No other subgroups were related to CHD mortality.

**Missing analysis**

The extent of missing covariate data was evaluated in a sample (n = 49,512) without individuals < 20 years, and the analytic sample (n = 13,731). Overall, no differences in socio-demographics, behavioral factors, or healthcare utilization and insurance coverage were found between the full and analytic sample.

**Discussion**

The present study was an analysis of adults without self-identified kidney or liver conditions in the United States from 1999 to 2016. We aimed to identify the relationship between well-known surrogates of kidney and liver dysfunction with (and without) MetS, and all-cause, and CHD mortality. Among the one-third of U.S.
adults who have MetS, most biomarker ratios tended to be higher than that of individuals without MetS. Positive associations with all-cause mortality were observed for elevated UACR or albuminuria, and elevated AST-ALT, both with and without MetS. Positive associations with CHD mortality were observed for elevated UACR, and elevated AST-ALT, with MetS. As well, positive associations with all-cause mortality for elevated BUN-CR without MetS, and; positive associations with all-cause mortality for elevated GGT-ALP with MetS in participants without CVD, diabetes, or hypertension.

All-cause/CHD mortality was not associated with prevalent MetS (without elevated biomarker ratios), nor groups with neither elevated biomarker ratio nor MetS. As an intermediary step, a sensitivity analysis was performed (see Additional file 1: Table S1) in a fully adjusted logistic regression of the odds between the combination of MetS with elevation in biomarker ratios on CVD, which did not change the relationship.

### Clinical application

Similar to the findings from this study, the presence of elevated kidney or liver biomarkers has previously been found to be associated with a higher risk of all-cause mortality [18, 20, 22, 34], or cardiovascular mortality [17, 19, 24, 25]. Furthermore, a UACR or BUN-CR test enables the prediction of renal dysfunction or nephropathy [27, 42], including the evaluation of CVD events [8, 9, 18–21, 38]. In terms of the surrogates for liver dysfunction, there is no single biomarker that can definitively diagnose or distinguish diseases of the liver [5, 6, 22, 23, 43]. Currently, GGT on its own has limited specificity [6, 22], and is known to be sensitive to variations in alcohol intake [42]; however, GGT-ALP could help to ascertain whether the source of a disease could be due to liver or bone pathology [22].

Routine measurements of AST and ALT support the detection of liver dysfunction [5, 6, 44]. ALT activity, however, is specific to the liver, while AST is systemic and can be found in the brain, heart, liver, lungs, kidneys, skeletal muscles, and pancreas [42]. Although AST is a less specific indicator of hepatic injury than ALT, as a ratio—AST-ALT—they tend to elevate simultaneously in cases of hepatitis, cirrhosis, hepatobiliary disorders, or necroinflammation [5, 42, 44]. In this analysis, we observed that elevated AST-ALT with and without MetS was positively associated with all-cause mortality, and; positively associated with CHD mortality in the presence...
of MetS, while elevated GGT-ALP with MetS was positively associated with all-cause mortality.

Evidence in support of the use of elevated AST-ALT ratio in mortality, MetS, or its comorbid risk factors is mixed, and an area of ongoing research [22, 24, 29, 45–47]. In MetS positive cases, the AST-ALT ratio tends to be lower, which is consistent with previous studies [15, 29]. Insulin resistance, fat infiltration of the liver, or visceral adiposity [15], and medical prescriptions [24] may explain the relationship. Studies [6, 15, 24, 25] have also reported a long-term risk for metabolic disorders with normal or abnormal ALT. Taken together, however, elevated AST-ALT alongside elevated GGT or ALP has been shown to improve the identification of severe cardiometabolic disease [5, 48, 49]. Further studies are needed to investigate the potential of these biomarkers and their appropriate reference values to predict population health risks more accurately [6, 16, 22, 24, 25, 34], and may be particularly valuable for risk stratification of obesity phenotypes [47].

**Strengths and limitations**

The main advantages of this study were: its multicycle cross-sectional design and mortality linkage, which allowed for the determination of prevalence of elevated biomarker levels and 6.9 year average survival estimates with adjustment for a host of potential confounders. The main limitations of this study were the single baseline measure of analytes and that directionality and causality could not be determined for the inter-relationship between biomarkers and MetS. Despite a large representative sample, our analyses were limited to thresholds of biomarker ratios, rather than a full examination of dose–response patterns.

**Conclusion**

This study is among a few studies to use a national representative sample of the U.S. adult population to compare the effects of biomarkers on MetS, and their related effects on all-cause and CHD mortality. MetS with albuminuria or with elevated AST-ALT was positively related to CHD mortality, while albuminuria, and elevated AST-ALT, with and without MetS, were positively related to all-cause death. Further work is therefore necessary to understand the utility of kidney and liver biomarker ratios in the prediction of all-cause and cause-specific mortality. Future longitudinal studies should make available the in-depth tracking and analyses of the long-term impact of these components in subpopulations of at-risk

### Table 4 Association between CHD mortality and kidney or liver biomarker ratio with or without MetS (referent)

| Biomarkers | Groups | Unadjusted | Adjusted | Adjusted |
|------------|--------|------------|----------|----------|
|            | MetS status | High biomarker ratio | Hazard ratios | 95% confidence interval | Hazard ratios | 95% confidence interval | Hazard ratios | 95% confidence interval |
|            | No     | No         | 1.00 (REF) – | – | 1.00 (REF) – | – |
|            | No     | Yes        | 1.92 | 1.03 to 3.61 | 1.22 | 0.66 to 2.24 | 0.67 | 0.33 to 1.39 |
|            | Yes    | No         | 0.97 | 0.64 to 1.47 | 0.83 | 0.54 to 1.26 | 0.77 | 0.46 to 1.31 |
|            | Yes    | Yes        | 1.76 | 1.02 to 3.02 | 1.67 | 1.05 to 2.67 | 1.71 | 0.95 to 3.09 |
| UACR       | No     | No         | 1.00 (REF) – | – | 1.00 (REF) – | – |
|            | No     | Yes        | 1.43 | 0.74 to 2.77 | 2.12 | 1.12 to 4.04 | 1.90 | 0.84 to 4.29 |
|            | Yes    | No         | 1.20 | 0.78 to 1.83 | 1.17 | 0.77 to 1.77 | 1.26 | 0.76 to 2.09 |
|            | Yes    | Yes        | 0.79 | 0.44 to 1.44 | 0.81 | 0.40 to 1.64 | 0.59 | 0.22 to 1.55 |
| BUN-CR     | No     | No         | 1.00 (REF) – | – | 1.00 (REF) – | – |
|            | No     | Yes        | 1.87 | 0.87 to 4.03 | 1.60 | 0.80 to 3.21 | 1.42 | 0.58 to 3.45 |
|            | Yes    | No         | 1.15 | 0.79 to 1.68 | 1.11 | 0.77 to 1.61 | 1.19 | 0.74 to 1.93 |
|            | Yes    | Yes        | 1.11 | 0.59 to 2.09 | 0.81 | 0.45 to 1.48 | 0.70 | 0.33 to 1.47 |
| GGT-ALP    | No     | No         | 1.00 (REF) – | – | 1.00 (REF) – | – |
|            | No     | Yes        | 1.25 | 0.69 to 2.26 | 1.40 | 0.76 to 2.58 | 1.52 | 0.74 to 3.11 |
|            | Yes    | No         | 0.94 | 0.65 to 1.35 | 0.88 | 0.62 to 1.24 | 0.92 | 0.59 to 1.45 |
|            | Yes    | Yes        | 2.86 | 1.58 to 5.19 | 2.80 | 1.62 to 4.86 | 3.11 | 1.49 to 6.49 |

Data derived from NHANES 1999–2015; referent group has neither elevated biomarker ratio nor MetS. Covariates include age, sex, ethnicity, education, income ratio, alcohol use, smoking, hospital visits, insurance coverage, self-rated health, and physical activity.

a Unadjusted model of the analytic subsample (n = 1212; n = 201 deaths)
b Fully adjusted model of the analytic subsample (n = 1212; n = 201 deaths)
c Fully adjusted model of a subsample without self-reported CVD, diabetes, or hypertension (n = 968; n = 134 deaths)
adults in order to improve risk stratification for chronic disease management.

**Abbreviations**

CHD: Coronary heart disease; NHANES: National health and nutrition examination survey; CVD: Cardiovascular disease; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; NAFLD: Non-alcoholic fatty liver disease; ALD: Alcoholic liver disease; LMF: Linked mortality files; CV: Coefficient of variation; BUN: Blood urea nitrogen; CR: Serum creatinine; HDL: High density lipoprotein; UA: Urinary albumin; UCR: Urinary creatinine; NDI: National death index; NCHS: National center for health statistics; PA: Physical activity; MET: Metabolic equivalent task; ICD: International classification of diseases.

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s12872-021-02160-w](https://doi.org/10.1186/s12872-021-02160-w).

**Table 5** Association between CHD mortality and kidney or liver biomarker ratio without or with MetS (referent)

| Biomarkers | Groups | MetS status | High biomarker ratio | Unadjusteda Hazard ratios 95% confidence interval | Adjustedb Hazard ratios 95% confidence interval | Adjustedc Hazard ratios 95% confidence interval |
|------------|--------|-------------|----------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| UACR       | Yes No | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – |
|            | No No   | 1.03 0.68 to 1.56 | 1.21 0.79 to 1.85 | 1.30 0.77 to 2.19 |
|            | Yes Yes | 1.98 1.14 to 3.44 | 1.48 0.81 to 2.69 | 0.87 0.41 to 1.87 |
|            | Yes Yes | 1.81 1.11 to 2.96 | 2.03 1.28 to 3.22 | 2.22 1.24 to 3.97 |
| BUN-CR     | Yes No | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – |
|            | No No   | 0.84 0.55 to 1.28 | 0.86 0.57 to 1.29 | 0.79 0.48 to 1.31 |
|            | No Yes  | 1.20 0.63 to 2.27 | 1.82 1.00 to 3.29 | 1.50 0.67 to 3.35 |
|            | Yes Yes | 0.66 0.32 to 1.36 | 0.69 0.32 to 1.49 | 0.47 0.17 to 1.28 |
| GGT-ALP    | Yes No | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – |
|            | No No   | 0.87 0.60 to 1.26 | 0.90 0.62 to 1.31 | 0.84 0.52 to 1.35 |
|            | No Yes  | 1.62 0.79 to 3.34 | 1.45 0.78 to 2.68 | 1.19 0.51 to 2.78 |
|            | Yes Yes | 0.96 0.49 to 1.87 | 0.73 0.42 to 1.29 | 0.58 0.31 to 1.11 |
| AST-ALT    | Yes No | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – | 1.00 (REF) – 1.00 (REF) – 1.00 (REF) – |
|            | No No   | 1.07 0.74 to 1.54 | 1.40 0.76 to 2.58 | 1.09 0.69 to 1.71 |
|            | No Yes  | 1.33 0.73 to 2.45 | 0.88 0.62 to 1.24 | 1.65 0.75 to 3.62 |
|            | Yes Yes | 3.06 1.73 to 5.42 | 3.20 1.86 to 5.51 | 3.38 1.64 to 6.98 |

Data derived from NHANES 1999–2015; referent group has prevalent MetS. Covariates include age, sex, ethnicity, education, income ratio, alcohol use, smoking, hospital visits, insurance coverage, self-rated health, and physical activity.

a Unadjusted model of the analytic subsample (n = 1212); n = 201 deaths

b Fully adjusted model of the analytic subsample (n = 1212); n = 201 deaths

c Fully adjusted model of a subsample without self-reported CVD, diabetes, or hypertension (n = 968); n = 134 deaths

**Acknowledgements**

None. Authors’ information AO is a Doctoral Candidate in the Faculty of Health—School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada. JK is an Associate Professor in the Faculty of Health—School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada. CA is an Associate Professor in the Faculty of Health—School of Kinesiology and Health Science, York University, Toronto, Ontario, Canada.

**Authors’ contributions**

AO analyzed and interpreted the disease and mortality data. AO wrote the draft of the manuscript with CA and JK providing critical revisions to the article and analyses. CA and JK read and approved the findings and the final version of the article to be published. All authors read and approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

The datasets generated and/or analysed during the current study are available from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention [https://www.cdc.gov/nchs/nhanes]. Public-use Linked Mortality Files (LMF) is available for the 1999–2014 NHANES [https://www.cdc.gov/nchs/data-linkage/mortality-public.htm].

**Declarations**

Ethics approval and consent to participate

Ethics approval was obtained from the National Center for Health Statistics Research Ethics Review Board (ERB) for NHANES 1999–2004 (Protocol #98-12),
NHANES 2005–2010 (Protocol #2005-06), NHANES 2011–2016 (Protocol #2011-17) on which data for this analysis was used. Additional details are available at: https://www.cdc.gov/nchs/nhanes/irba98.htm. Informed, written consent was obtained from all participants. This study is an analysis of NHANES publicly available anonymized data, and thus, does not require further ethical review from the York University institutional review board.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests. None.

References
1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato NM, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–5.
2. Aguilar M, Bhuket T, Torres S, Liu B, Wong RY. Prevalence of the metabolic syndrome in the United States, 2003–2012. JAMA. 2015;313(19):1973–9.
3. Moore JD. Metabolic syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Prev Chronic Dis. 2017;14:E24.
4. Huang PL. A comprehensive definition for metabolic syndrome. Dis Models Mech. 2009;2(5–6):231–7.
5. Hall P, Cash J. What is the real function of the liver ‘function’ tests? Ulster Med J. 2012;81(1):30–6.
6. Goessling W, Massaro JM, Vasan RS, D’Agostino RB Sr, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135(S6):1935–1944. e1.
7. Hsu C, McCulloch CE, Darbinian J, Go AS, Inbaran C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165(8):923–8.
8. Liu X, Wang K, Wang L, Tsilimingras D. Microalbuminuria, macroalbuminuria and uncontrolled blood pressure among diagnosed hypertensive patients: the aspect of racial disparity in the NHANES study. Hypertens Res. 2013;36(12):1100–6.
9. Seliger SL, Salimi S, Pierre V, Giffuni J, Katzel L, Parsa A. Microvascular endothelial dysfunction is associated with albuminuria and CKD in older adults. BMC Nephrol. 2016;17:82.
10. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol. 2011;20(3):135–42.
11. Guerner V, Rubio-Ruz ME. Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Aging Health Syst Biol Perspect. 2015;4:99–106.
12. Emdin CA, Anderson SG, Woodward M, Rahimi K. Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies. J Am Coll Cardiol. 2015;66(14):1552–62.
13. Marland AL, McCaffery JM, Muldoon MF, Manuck S. Systemic inflammation and the metabolic syndrome among middle-aged community volunteers. Metabolism. 2010;59(12):1801–8.
14. Grundy SM, Brewer HB, Cleeman JL, Smith SC Jr, Lenfant C. Definition of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(2):e13–8.
15. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D’Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005;54(11):340–7.
16. Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrol Dial Transplant. 2019;34(3):449–57.
17. Paik J, Golab P, Younoszai Z, Mishra A, Trimble G, Younossi Z. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int. 2019;39(2):342–52.
18. Anderson D, Mitrpanorm MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med. 2004;116(7):466–73.
19. Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore SS, et al. Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med. 2006;166(10):1343–42.
20. Pannullo G, Torres D, Testani JM, Almasio PL, Bellanca M, Pizzo G, et al. Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. Intern Emerg Med. 2015;10(8):965–72.
21. Lee M, Saver JL, Chang K, Liao H, Chang S, Oviabiegbu B. Impact of Microalbuminuria on Incident Stroke. Stroke. 2010;41(11):2625–31.
22. Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(1):187–201.
23. Kălsch J, Bechmann LP, Heider D, Best J, Manka P, Kălsch H, et al. Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Scand J Clin Lab Invest. 2015;75(1):1–9.
24. Weng SF, Kaji J, Guha IN, Qureshi N. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment. Open Heart. 2015;2(1):e000272.
25. Zoppini G, Cacciatori V, Negri C, Stoico V, Lippi G, Tarnger G, et al. The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes. Medicine (Baltimore). 2016;95(43). e4821. https://doi.org/10.1097/MD. 0000000000004821.
26. Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, Levey AS, et al. Calibration of Serum Creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50(6):918–26.
27. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Questionnaire, Datasets, and Related Documentation. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2020.
28. Links JM, Groopman JD. Biomarkers of Exposure, Effect, and Susceptibility. In: McQueen CA, ed. Comprehensive Toxicology (Second Edition). Oxford: Elsevier; 2010:225–243.
29. Yadav D, Choi E, Ahn SV, Baik SK, Cho Y, Koh SB, et al. Incremental Predictive Value of Serum AST-to-ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. PLOS ONE. 2016;11(8):e0161304.
30. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Methods and Analytic Guidelines. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2020.
31. Lacher DA, Hughes JP, Carroll MD. Biological variation of laboratory analytes based on the 1999-2002 National Health and Nutrition Examination Survey. Natl Health Stat Rep. 2010(21):1–7.
32. Pfeiffer CM, Lacher DA, Schleicher RL, Johnson C, Yetley EA. Challenges and lessons learned in generating and interpreting NHANES nutritional biomarker data. Adv Nutr. 2017;8(2):290–307.
33. Hughes HK, Kahl LK. The Harriet lane handbook. Elsevier, 2018.
34. Pho N, Manrai AK, Leppert JT, Chertow GM, Ioannidis JPA, Patel CJ. Association of 152 biomarker reference intervals with all-cause mortality in participants of a general United States Survey from 1999 to 2010. Clin Chem. 2021;67:500–7.
35. National Center for Health Statistics. Office of Analysis and Epidemiology. The Linkage of National Center for Health Statistics Survey Data to the National Death Index — 2015 Linked Mortality File (LMF). Methodology Overview and Analytic Considerations, March 2019. Hyattsville, Maryland.
36. Karliliddé J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens. 2004;17(10):896–93.
37. Tonelli M, Curhan G, Pfeffer MA, Sacks F, Thadani R, Melamed ML, et al. Relation Between Alkaline Phosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality. Circ. 2009;120(18):1784–92.
38. Brisco MA, Coca SG, Chen J, Owens AT, MaCaeley BD, Kimmel SE, et al. Blood Urea Nitrogen/Creatinine Ratio Identifies a High-Risk but Potentially Reversible Form of Renal Dysfunction in Patients With Decompensated Heart Failure. Circ. 2015;136(2):233–9.
39. Le MH, Yeo YH, Henry L, Nguyen MH. Nonalcoholic Fatty Liver Disease and Renal Function Impairment: A Cross-Sectional Population-Based
Study on Its Relationship From 1999 to 2016. Hepatol Commun. 2019;3(10):1334–1346.
40. Sundström J, Risérus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ. 2006;332(7546):878–82.
41. Wong CR, Lim JK. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. Clin Liver Dis. 2018;12(2):39–44.
42. Provincial Health Services Authority (PHSA). British Columbia Cancer Agency: Clinical Pharmacy Guide: Cancer Drug Treatment Assessment and Review 5th Edition; 2019.
43. Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci. 2010;55(3):560–78.
44. Walker HK, Hall WD, Hurst JW, eds. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Boston: Butterworths; 1990.
45. Ohgo H, Yokoyama H, Hirose H, Kawabe H, Saito I, Tomita K, et al. Significance of ALT/AST ratio for specifying subjects with metabolic syndrome in its silent stage. Diabetes Metab Syndr. 2009;3(1):3–6.
46. Pacifico L, Ferraro F, Bonci E, Anania C, Romaggioli S, Chiesa C. Upper limit of normal for alanine aminotransferase: Quo vadis? Clin Chim Acta. 2013;422:29–39.
47. Phillips CM. Metabolically healthy obesity: definitions, determinants, and clinical implications. Rev Endocr Metab Disord. 2013;14(3):219–27.
48. Alempijevic T, Krstic M, Jescic R, Jovanovic I, Milutinovic AS, Kovačević N, et al. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol. 2009;15(5):591–4.
49. Koenig G, Seneff S. Gamma-glutamyltransferase: a predictive biomarker of cellular antioxidant inadequacy and disease risk. Dis Markers. 2015;2015:818570.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.